Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1


      We studied the longitudinal relation between disease severity and titers of antigen-specific IgG subclasses in sera of patients with myasthenia gravis and antibodies to Muscle Specific Kinase (MuSK MG). Six patients were included of whom 55 samples had been collected during 2.5–13.4 years. Anti-MuSK antibodies were determined by ELISA and with a cell-based immunofluorescence assay. Disease severity was scored on a semi continuous scale. Only antigen-specific IgG4, and not IgG1, titers were significantly associated with disease severity in a linear mixed effect model (p = 0.036). Levels of IgG4 antibodies were above IgG1 in all samples except in one patient who went into clinical remission while switching from IgG4 to IgG1. The results support an important role for IgG4 in the pathogenesis of MuSK MG, in contrast to MG with anti-acetylcholine receptor antibodies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Neuroimmunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aalberse R.C.
        • van der Gaag R.
        • van Leeuwen J.
        Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response.
        J. Immunol. 1983; 130: 722-726
        • Bartoccioni E.
        • Scuderi F.
        • Minicuci G.M.
        • Marino M.
        • Ciaraffa F.
        • Evoli A.
        Anti-MuSK antibodies: Correlation with myasthenia gravis severity.
        Neurology. 2006; 67: 505-507
        • Bhol K.
        • Natarajan K.
        • Nagarwalla N.
        • Mohimen A.
        • Aoki V.
        • Ahmed A.R.
        Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity.
        Proc. Natl. Acad. Sci. USA. 1995; 92: 5239-5243
        • Brooke M.H.
        A Clinician's View of Neuromuscular Diseases.
        2 ed. Williams & Wilkins, Baltimore1986
        • DeChiara T.M.
        • Bowen D.C.
        • Valenzuela D.M.
        • Simmons M.V.
        • Poueymirou W.T.
        • Thomas S.
        • Kinetz E.
        • Compton D.L.
        • Rojas E.
        • Park J.S.
        • Smith C.
        • DiStefano P.S.
        • Glass D.J.
        • Burden S.J.
        • Yancopoulos G.D.
        The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo.
        Cell. 1996; 85: 501-512
        • Evoli A.
        • Tonali P.A.
        • Padua L.
        • Monaco M.L.
        • Scuderi F.
        • Batocchi A.P.
        • Marino M.
        • Bartoccioni E.
        Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
        Brain. 2003; 126: 2304-2311
        • Futei Y.
        • Amagai M.
        • Ishii K.
        • Kuroda-Kinoshita K.
        • Ohya K.
        • Nishikawa T.
        Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus.
        J. Dermatol. Sci. 2001; 26: 55-61
        • Hamano H.
        • Kawa S.
        • Horiuchi A.
        • Unno H.
        • Furuya N.
        • Akamatsu T.
        • Fukushima M.
        • Nikaido T.
        • Nakayama K.
        • Usuda N.
        • Kiyosawa K.
        High serum IgG4 concentrations in patients with sclerosing pancreatitis.
        N. Engl. J. Med. 2001; 344: 732-738
        • Hillman M.
        • Törn C.
        • Thorgeirsson H.
        • Landin-Olsson M.
        IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes.
        Diabetologia. 2004; 47: 1984-1989
        • Jaretzki A.
        • Barohn R.J.
        • Ernstoff R.M.
        • Kaminski H.J.
        • Keesey J.C.
        • Penn A.S.
        • Sanders D.B.
        Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.
        Neurology. 2000; 55: 16-23
        • Jha S.
        • Xu K.
        • Maruta T.
        • Oshima M.
        • Mosier D.R.
        • Atassi M.Z.
        • Hoch W.
        Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK).
        J. Neuroimmunol. 2006; 175: 107-117
        • Kong X.C.
        • Barzaghi P.
        • Ruegg M.A.
        Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference.
        EMBO Rep. 2004; 5: 183-188
        • Matsumoto T.
        • Shima M.
        • Fukuda K.
        • Nogami K.
        • Giddings J.C.
        • Murakami T.
        • Tanaka I.
        • Yoshioka A.
        Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease.
        Thromb. Res. 2001; 104: 381-388
        • McConville J.
        • Farrugia M.E.
        • Beeson D.
        • Kishore U.
        • Metcalfe R.
        • Newsom-Davis J.
        • Vincent A.
        Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.
        Ann. Neurol. 2004; 55: 580-584
        • Oosterhuis H.J.
        • Limburg P.C.
        • Hummel-Tappel E.
        • The T.H.
        Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients.
        J. Neurol. Sci. 1983; 58: 371-385
        • Selcen D.
        • Fukuda T.
        • Shen X.M.
        • Engel A.G.
        Are MuSK antibodies the primary cause of myasthenic symptoms?.
        Neurology. 2004; 62: 1945-1950
        • Shiraishi H.
        • Motomura M.
        • Yoshimura T.
        • Fukudome T.
        • Fukuda T.
        • Nakao Y.
        • Tsujihata M.
        • Vincent A.
        • Eguchi K.
        Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
        Ann. Neurol. 2005; 57: 289-293